New drug plus carboplatin for advanced breast cancer with her2
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug (SHR-1811) combined with a standard chemotherapy drug (carboplatin) for advanced breast cancer that shows HER2, even at low levels. It may offer a new option for people whose cancer has stopped responding to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 to 75.
- Your breast cancer must be advanced (spread or not removable by surgery) and show some level of HER2 protein (even low or ultra-low).
- You must have already tried at least one standard treatment that no longer controls the cancer.
- If you have HER2-positive cancer, you cannot have had certain newer antibody-drug conjugates (like T-DXd). If you have low HER2, you cannot have had any ADC treatment.
- You need to be in good general health (able to do light activity) and have adequate organ function.
- You must agree to use effective birth control during the study and for 4 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This trial tests a new drug (SHR-A1811) combined with fulvestrant, with or without another drug (HS-10352), for people with advanced breast cancer that has not been treated before. The goal is to see if these combinations can help control the cancer.
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
This study tests a new targeted drug (SHR-A1811) for breast cancer that has very low HER2 levels. The drug is designed to attack cancer cells with this specific marker, and the study aims to see if it can help slow the cancer's growth.
This study tests a new drug called SHR-A1811, given by different methods, to find the best way to treat advanced HER2-positive breast cancer. It may help if you have had few treatments so far and have not had this type of drug before.
This trial tests a new drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after the first four rounds of chemotherapy before surgery. The goal is to see if this drug can improve outcomes for patients who need a different treatment approach.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.